Tech Company Financing Transactions
GC Therapeutics Funding Round
GC Therapeutics closed a $65 million Series A funding round on 9/19/2024. Investors included Cormorant Asset Management, Andreessen Horowitz and Mubadala.
Transaction Overview
Company Name
Announced On
9/19/2024
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
610 Main Street
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Invented and developed by a world-class team of scientists in the lab of George Church, Ph.D., at the Wyss Institute of Harvard University, GCTx's induced pluripotent stem cell (iPSC) programming platform, TFome�, integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Parastoo Khoshakhlagh
Chief Scientific Officer
Alex Ng
Co-Founder
George Church
Co-Founder
Cory Smith
Browse more venture capital transactions:
Prev: 9/19/2024: Mercor venture capital transaction
Next: 9/19/2024: Fathom venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs